Topics

FDA Grants Regenerative Advanced Therapy Designation to Adaptimmune’s Investigational Synovial Sarcoma Treatment

10:19 EST 4 Dec 2019 | Speciality Pharma Journal

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, FDA granted Orphan …

Original Article: FDA Grants Regenerative Advanced Therapy Designation to Adaptimmune’s Investigational Synovial Sarcoma Treatment

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Regenerative Advanced Therapy Designation to Adaptimmune’s Investigational Synovial Sarcoma Treatment"

Quick Search

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...